In Defense of Phosphodiesterase 5 Inhibitors-Reply.

Autor: Sodhi M; Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Mikelberg FS; Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Etminan M; Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Publikováno v: JAMA ophthalmology [JAMA Ophthalmol] 2022 Sep 01; Vol. 140 (9), pp. 908-909.

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.

Autor: Etminan M; Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Sodhi M; Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Mikelberg FS; Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Maberley D; Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Ophthalmology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Publikováno v: JAMA ophthalmology [JAMA Ophthalmol] 2022 May 01; Vol. 140 (5), pp. 480-484.

Association of Gabapentin or Pregabalin Use and Incidence of Acute Angle-closure Glaucoma.

Autor: Browne MJ; Department of Ophthalmology and Visual Sciences., Zakrzewski H; Department of Experimental Surgery, McGill University, Montreal, QC, Canada., Carleton B; Department of Pediatrics, Division of Translational Therapeutics, Faculty of Medicine.; BC Children's Hospital Research Institute, University of British Columbia.; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, BC., Etminan M; Department of Ophthalmology and Visual Sciences., Mikelberg FS; Department of Ophthalmology and Visual Sciences.

Publikováno v: Journal of glaucoma [J Glaucoma] 2019 Sep; Vol. 28 (9), pp. 777-779.

Caretteristiche morfometriche della papilla ottica nei pazienti con glaucoma ad alta pressione e glaucoma a pressione normale

Autor: Iester, Michele, Mikelberg, Fs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3710::3b91117acf68dd67111391641cd6b782
http://hdl.handle.net/11567/303729

Morphometric parameters in high-tension and normal-tension glaucoma. Correlation with visual field indices

Autor: Iester, Michele, Mikelberg, Fs, Courtright, P, Drance, Sm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3710::8ac15b78666ff3cf0b3409af545d27e9
http://hdl.handle.net/11567/303039